AAAAAA

   
Results: 1-10 |
Results: 10
ACADEMIC ONCOLOGY AND THE FORCES OF THE MARKETPLACE - CRISIS CLOAKS OPPORTUNITY
Authors: MEISENBERG BR
Citation: Br. Meisenberg, ACADEMIC ONCOLOGY AND THE FORCES OF THE MARKETPLACE - CRISIS CLOAKS OPPORTUNITY, Academic medicine, 73(8), 1998, pp. 833-835
REDUCED CHARGES AND COSTS ASSOCIATED WITH OUTPATIENT AUTOLOGOUS STEM-CELL TRANSPLANTATION
Authors: MEISENBERG BR FERRAN K HOLLENBACH K BREHM T JOLLON J PIRO LD
Citation: Br. Meisenberg et al., REDUCED CHARGES AND COSTS ASSOCIATED WITH OUTPATIENT AUTOLOGOUS STEM-CELL TRANSPLANTATION, Bone marrow transplantation, 21(9), 1998, pp. 927-932
COMPLICATIONS ASSOCIATED WITH CENTRAL VENOUS CATHETERS USED FOR THE COLLECTION OF PERIPHERAL-BLOOD PROGENITOR CELLS TO SUPPORT HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL RESCUE
Authors: MEISENBERG BR CALLAGHAN M SLOAN C SAMPSON L MILLER WE MCMILLAN R
Citation: Br. Meisenberg et al., COMPLICATIONS ASSOCIATED WITH CENTRAL VENOUS CATHETERS USED FOR THE COLLECTION OF PERIPHERAL-BLOOD PROGENITOR CELLS TO SUPPORT HIGH-DOSE CHEMOTHERAPY AND AUTOLOGOUS STEM-CELL RESCUE, Supportive care in cancer, 5(3), 1997, pp. 223-227
OUTPATIENT HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL RESCUE FOR HEMATOLOGIC AND NONHEMATOLOGIC MALIGNANCIES
Authors: MEISENBERG BR MILLER WE MCMILLAN R CALLAGHAN M SLOAN C BREHM T KOSTY MP KROENER J LONGMIRE R SAVEN A PIRO LD
Citation: Br. Meisenberg et al., OUTPATIENT HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS STEM-CELL RESCUE FOR HEMATOLOGIC AND NONHEMATOLOGIC MALIGNANCIES, Journal of clinical oncology, 15(1), 1997, pp. 11-17
AN ALL ORAL ANTIEMETIC REGIMEN FOR PATIENTS UNDERGOING HIGH-DOSE CHEMOTHERAPY WITH PERIPHERAL-BLOOD STEM-CELL TRANSPLANT
Authors: FRAKES LA BREHM TL KOSTY MP MILLER WE MCMILLAN RL MASON J MEISENBERG BR
Citation: La. Frakes et al., AN ALL ORAL ANTIEMETIC REGIMEN FOR PATIENTS UNDERGOING HIGH-DOSE CHEMOTHERAPY WITH PERIPHERAL-BLOOD STEM-CELL TRANSPLANT, Bone marrow transplantation, 20(6), 1997, pp. 473-478
TANDEM CYCLES OF HIGH-DOSE CHEMOTHERAPY (HDC) WITH PERIPHERAL-BLOOD PROGENITOR-CELL RESCUE (PBPCR) FOR PATIENTS WITH RELAPSED OR HIGH-RISK LYMPHOMA
Authors: RAJA N MILLER WE MCMILLAN R KOSTY MP SAVEN A MEISENBERG BR MASON JR
Citation: N. Raja et al., TANDEM CYCLES OF HIGH-DOSE CHEMOTHERAPY (HDC) WITH PERIPHERAL-BLOOD PROGENITOR-CELL RESCUE (PBPCR) FOR PATIENTS WITH RELAPSED OR HIGH-RISK LYMPHOMA, Blood, 90(10), 1997, pp. 4576-4576
MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) IN SUPPORT OF TANDEM CYCLES OF HIGH-DOSE CHEMOTHERAPY (HDC)
Authors: MEISENBERG BR MILLER WE MCMILLAN R
Citation: Br. Meisenberg et al., MOBILIZED PERIPHERAL-BLOOD PROGENITOR CELLS (PBPC) IN SUPPORT OF TANDEM CYCLES OF HIGH-DOSE CHEMOTHERAPY (HDC), Bone marrow transplantation, 18(6), 1996, pp. 1087-1093
HIGH-DOSE IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE WITH AUTOLOGOUS STEM-CELL SUPPORT
Authors: MEISENBERG BR
Citation: Br. Meisenberg, HIGH-DOSE IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE WITH AUTOLOGOUS STEM-CELL SUPPORT, Journal of clinical oncology, 13(7), 1995, pp. 1826-1826
RANDOMIZED TRIAL OF HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE-MARROW SUPPORT AS ADJUVANT THERAPY FOR HIGH-RISK, MULTI-NODE-POSITIVE MALIGNANT-MELANOMA
Authors: MEISENBERG BR ROSS M VREDENBURGH JJ JONES R SHPALL EJ SEIGLER HF CONIGLIO DM WU K PETERS WP
Citation: Br. Meisenberg et al., RANDOMIZED TRIAL OF HIGH-DOSE CHEMOTHERAPY WITH AUTOLOGOUS BONE-MARROW SUPPORT AS ADJUVANT THERAPY FOR HIGH-RISK, MULTI-NODE-POSITIVE MALIGNANT-MELANOMA, Journal of the National Cancer Institute, 85(13), 1993, pp. 1080-1085
GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) FOR MUSTARD-INDUCED BONE-MARROW SUPPRESSION
Authors: MEISENBERG BR MONROY RL MELARAGNO AJ
Citation: Br. Meisenberg et al., GRANULOCYTE-COLONY-STIMULATING FACTOR (G-CSF) FOR MUSTARD-INDUCED BONE-MARROW SUPPRESSION, Military medicine, 158(7), 1993, pp. 470-474
Risultati: 1-10 |